Jun 25 |
Why Drugmaker Eli Lilly Is Partnering With ChatGPT Maker OpenAI
|
Jun 25 |
AI Work Assistants Need a Lot of Handholding
|
Jun 25 |
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
|
Jun 25 |
Lilly gains approval of lebrikizumab in Canada for atopic dermatitis
|
Jun 25 |
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2
|
Jun 25 |
Eli Lilly collaborates with OpenAI for medicines against drug-resistant bacteria
|
Jun 25 |
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
|
Jun 25 |
Novo Nordisk Rises as Wegovy Is Approved in China
|
Jun 25 |
From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles
|
Jun 25 |
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
|